

# COVID-19 ECHO update Oct 28 2020

---

Brigg Reilley MPH

Brigg.Reilley@ihs.gov

No disclosures

Opinions expressed only my own

# CDC and MMWR updates

---

- Flu testing algorithm updates and resources
- COVID-19 Hospitalizations among healthcare professionals
- Excess deaths associated with COVID-19
- COVID-19 deaths by race/ethnicity—Montana example

# Influenza (Flu)

Seasonal Influenza (Flu) > Health Professionals



## Seasonal Influenza (Flu)

About Flu +

Who is at High Risk for Flu Complications +

This Flu Season +

Prevent Flu +

Flu Vaccines Work +

Symptoms & Diagnosis +

Treatment +

Schools, Businesses & Travelers +

Flu Activity & Surveillance +

**Health Professionals** -

Health Care Workers Need A Flu Vaccine

## Information for Clinicians on Influenza Virus Testing

[Español](#) | [Other Languages](#)

### Testing and treatment of influenza when SARS-CoV-2 and influenza viruses are co-circulating

- **New** [Consolidated Clinical Algorithm for Outpatient Clinic or Emergency Department Patients with Acute Respiratory Illness Symptoms \(With or Without Fever\)](#)
- **New** [Clinical Algorithm for Outpatient Clinic or Emergency Department Patients with Acute Respiratory Illness Symptoms \(With or Without Fever\) Not Requiring Hospital Admission](#)
- **New** [Clinical Algorithm for Patients with Acute Respiratory Illness Symptoms Requiring Hospital Admission \(With or Without Fever\)](#)

### When to Test for Influenza

- [Guide for considering influenza testing when](#)

### What Influenza Virus Tests Are Available

- [Overview of influenza tests](#)
- [Influenza Virus Testing Methods](#)
- [Table 1: Influenza Virus Testing Methods](#)
- [Table 2: FDA-cleared and Available Rapid Influenza Diagnostic Tests](#)
- [Table 3: FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses](#)
- [Table 4. Multiplex Assays Authorized for Simultaneous Detection of Influenza Viruses and SARS-CoV-2](#)
- [Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection](#)
- [Information about Rapid Influenza Diagnostic Tests](#)

### Information for Laboratory Directors

# Influenza (Flu)

Seasonal Influenza (Flu) > Health Professionals



## Seasonal Influenza (Flu)

- About Flu +
- Who is at High Risk for Flu Complications +
- This Flu Season +
- Prevent Flu +
- Flu Vaccines Work +
- Symptoms & Diagnosis +
- Treatment +
- Schools, Businesses & Travelers +
- Flu Activity & Surveillance +
- Health Professionals** -

Health Care Workers Need A Flu Vaccine

## Information for Clinicians on Influenza Virus Testing

[Español](#) | [Other Languages](#)

### Testing and treatment of influenza when SARS-CoV-2 and influenza viruses are co-circulating

- **New** [Consolidated Clinical Algorithm for Outpatient Clinic or Emergency Department Patients with Acute Respiratory Illness Symptoms \(With or Without Fever\)](#)
- **New** [Clinical Algorithm for Outpatient Clinic or Emergency Department Patients with Acute Respiratory Illness Symptoms \(With or Without Fever\) Not Requiring Hospital Admission](#)
- **New** [Clinical Algorithm for Patients with Acute Respiratory Illness Symptoms Requiring Hospital Admission \(With or Without Fever\)](#)

### When to Test for Influenza

- [Guide for considering influenza testing when](#)

### What Influenza Virus Tests Are Available

- [Overview of influenza tests](#)
- [Influenza Virus Testing Methods](#)
- [Table 1: Influenza Virus Testing Methods](#)
- [Table 2: FDA-cleared and Available Rapid Influenza Diagnostic Tests](#)
- [Table 3: FDA-cleared Nucleic Acid Detection Based Tests for Influenza Viruses](#)
- [Table 4. Multiplex Assays Authorized for Simultaneous Detection of Influenza Viruses and SARS-CoV-2](#)
- [Information on Rapid Molecular Assays, RT-PCR, and other Molecular Assays for Diagnosis of Influenza Virus Infection](#)
- [Information about Rapid Influenza Diagnostic Tests](#)

### Information for Laboratory Directors



Centers for Disease Control and Prevention  
CDC 24/7: Saving Lives, Protecting People™

[A-Z Index](#)



[Advanced Search](#)

## Morbidity and Mortality Weekly Report (*MMWR*)

CDC



# COVID-19 – Associated Hospitalizations Among Health Care Personnel — COVID-NET, 13 States, March 1–May 31, 2020

*Early Release / October 26, 2020 / 69*

# Methods

---

Surveillance data from 14 states

March 1-May 31

28,972 patients

- of which 6,760 sampled,
  - of which 438 (5.9%) Healthcare professionals (HCPs)

# Results of 438 COVID-19 hospitalizations

---

67.4% HCPs had role with presumed direct patient contact

Average age 49 years

36% in a nursing role

90% one or more underlying conditions


72% female

52% non-Hispanic, black

7% American Indian Alaska Native

4% died

**FIGURE 2. Weighted percentage of personnel types\*, † among reported health care personnel (HCP) with COVID-19–associated hospitalizations (N = 438) — COVID–NET, 13 states, § March 1–May 31, 2020**







# Excess Deaths Associated with COVID-19, by Age and Race and Ethnicity — United States, January 26–October 3, 2020

*Weekly* / October 23, 2020 / 69(42);1522–1527

*On October 20, 2020, this report was posted online as an MMWR Early Release.*

Laura M. Dwyer, PhD; Amy M. Dwyer, PhD; Farida B. Akbar, MPH; Paul Cutter, PhD; Robert M. Anderson, PhD (View author affiliations)

# Findings

---

- Excess deaths every week since March
- 299,098 excess deaths, of which 2/3 attributed to COVID-19
- Highest number of excess deaths among 75-84 y.o. (94,646)
- Highest percentage above average among 25-44 (27%)
- 3,412 excess deaths among AI/AN, 29% above average (range by race/ethnicity 12%-54%)

## Interim Analysis of COVID-19 cases in Montana (as of 10/16/2020)

This report is an interim epidemiological review of COVID-19 cases in Montana. Data is analyzed based on information available as of October 16, 2020. Current case count at the time of analysis is:

**Case Count = 22,233**


This report is completed using data that is available during the time of analysis and there may be a delay between current case count and this report, due to rapidly changing updates. When data is limited to available information, number of cases included in analysis is indicated in graphs.

### Geographic Distribution

There are 22,233 cases of COVID-19 reported in all 56 counties in Montana. Most cases are reported in more populous counties. Yellowstone County and Flathead County have been the most impacted, reporting 22% and 11% of all reported cases, respectively. Gallatin (10%), Missoula (7%), Cascade (6%), and Big Horn (5%) counties report more than 1,000 cases each (Figure 1).

Figure 1: Map of Reported Montana COVID-19 cases\*


Reported COVID-19 Cases in Montana as of 10/16/2020



# Latest from Montana DoH

[HTTPS://DPHHS.MT.GOV/PORTALS/  
 85/PUBLICHEALTH/DOCUMENTS/C  
 DEPI/DISEASESATOZ/2019-  
 NCOV/COVID%20EPI%20PROFILE%  
 2010162020.PDF](https://DPHHS.MT.GOV/PORTALS/85/PUBLICHEALTH/DOCUMENTS/CDEPI/DISEASESATOZ/2019-NCOV/COVID%20EPI%20PROFILE%2010162020.PDF)


American Indian/Alaska Native percentage of total state population,  
cumulative COVID-19 hospitalizations and deaths,  
Montana as of 10/16/20




# IHS Dashboard Data update

---


Positive SARS-CoV-2 tests, IHS Dashboard, Aug 21-Oct 22, weekly



# Total SARS-CoV-2 tests, positive tests, and % tests positive, IHS Dashboard, Aug 21-Oct 22, by week




# Positive SARS-CoV-2 Tests per 10,000 User Population, by Area, Oct 9-Oct 22





**% of User Pop, % of cumulative SARS-CoV-2 burden,  
By Area, IHS Dashboard,**



# CDC and FDA COVID19 communication resources

---

<https://www.cdc.gov/coronavirus/2019-ncov/communication/index.html>

<https://www.fda.gov/media/142400/download>

## Communication Tools




Social distancing means putting space between yourself and others.

### Social Media Toolkit

Toolkit to help localize efforts in responding to the virus that causes COVID-19.


[Español](#)



### COVID-19 Microsite

Real-time COVID-19 information added to your website.

[Español](#)



### Digital Press Kit

A collection of media resources on COVID-19 response, published online.

## FDA Approved Tweets for Stakeholders



FDA has provided the following approved social media messages on topics related to COVID-19 to help as you share this important information with your members.

### FRAUDULENT PRODUCTS

1. .@US\_FDA is warning individuals and companies selling unapproved products with claims that they mitigate, prevent, treat, diagnose, or cure #COVID19. Learn more at <https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products>
2. Currently, there is no product approved, cleared, or licensed by FDA to treat or prevent #COVID19. Learn the facts at <https://www.fda.gov/consumers/health-fraud-scams/fraudulent-coronavirus-disease-2019-covid-19-products>
3. .@US\_FDA has a dedicated task force closely monitoring for fraudulent products in the market as part of our #COVID19 response. Learn more at <https://www.fda.gov/safety/report-problem-fda/reporting-unlawful-sales-medical-products-internet>
4. DYK! You can report anyone claiming their product can prevent or cure #COVID19 to @US\_FDA <https://www.fda.gov/safety/report-problem-fda/reporting-unlawful-sales-medical-products-internet>
5. Be careful. Don't believe everything you hear or read about #COVID19. Learn more from @US\_FDA <https://www.fda.gov/consumers/consumer-updates/beware-fraudulent-coronavirus-tests-vaccines-and-treatments>

To include an accompanying image with any of the above tweets, click any of the images below to visit the websites where each image can be downloaded.



- Prevention and general messages
- Fraudulent products
- Medical countermeasures
- “Multicultural”

# Thank you

---

